Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent (FRENCH24 ANIS)
2024-515181-14-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- May 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of piperacillin + tazobactam in Periampullary Carcinoma, surgical site infection (SSI), pancreatic fistula (POPF) and 1 more, sponsored by Rouen University Hospital. Primary endpoint: Organ/space surgical site infections with positive cultures. Planned start May 2026; status: authorised.
02
Drugs
piperacillin + tazobactam
03
Conditions
Periampullary Carcinomasurgical site infection (SSI)pancreatic fistula (POPF)Bile leak
Beyond the preview
Go deeper on 2024-515181-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515181-14-00.